Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure

Journal of Hypertension

Volumn 31, Issue 11, 2013, Pages 2309-2319

  Muñoz Pacheco, Paloma ^a   Ortega Hernández, Adriana ^a   Caro Vadillo, Alicia ^b   Casanueva Eliceiry, Sebastian ^a   Aragoncillo, Paloma ^a   Egido, Jesús ^c   Fernández Cruz, Arturo ^b   Gómez Garre, Dulcenombre ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

cardiac remodeling; eplerenone; matricellular proteins; preserved systolic function heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MATRIX METALLOPROTEINASE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; CARDIAC MUSCLE; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; HEART; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HEART; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIUM; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; SPIRONOLACTONE;

EID: 84885648331     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328364abd6     Document Type: Article

References (37)

1. Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004; 90:1229-1234.
2. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag 2011; 7:353-363.
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials. Eur Heart J 2009; 30:469-477.
4. Moore TD, Nawarskas JJ, Anderson JR. Eplerenone: A selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis 2003; 5:354-363.
5. Lalande S, Johnson BD. Diastolic dysfunction: A link between hypertension and heart failure. Drugs Today (Barc) 2008; 44:503-513.
6. Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf) 2008; 194:3-21.
7. Gómez-Garre D, González-Rubio ML, Munõz-Pacheco P, Caro-Vadillo A, Aragoncillo P, Fernández-Cruz A. Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction. Eur J Heart Fail 2010; 12:903-912.
8. Holycross BJ, Summers BM, Dunn RB, McCune SA. Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. Am J Physiol 1997; 273:H228-H233.
9. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23:1444-1451.
10. Gómez-Garre D, Herraiz M, González-Rubio ML, Bernal R, Aragoncillo P, Carbonell A, et al. Activation of peroxisome proliferator- activated receptor-a and -g in auricular tissue from patients with human failing heart due to ischemic cardiomyopathy. Eur J Heart Fail 2006; 8:154-161.
11. Jane-Lise S, Corda S, Chassagne C, Rappaport L. The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Fail Rev 2000; 5:239-250.
12. Okamoto H, Imanaka-Yoshida K. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther 2012; 30:e198-e209.
13. Gilmore TD. Introduction to NF-kB: players, pathways, perspectives. Oncogene 2006; 25:6680-6684.
14. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008; 52:1060-1067.
15. Fraccarollo D, Galuppo P, Schmidt I, Ertl G, Bauersachs J. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 2005; 67:97-105.
16. Masson S, Staszewsky L, Annoni G, Carlo E, Arosio B, Bai A, et al. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. J Card Fail 2004; 10:433-441.
17. Kambara A, Holycross BJ, Wung P, Schanbacher B, Ghosh S, McCune SA, et al. Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol 2003; 41:830-837.
18. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17:634-642.
19. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: A double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010; 12:874-882.
20. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162:966-972.
21. Rysä J, Leskinen H, Ilves M, Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 2005; 45:927-933.
22. Boluyt MO, Bing OH, Lakatta EG. The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Eur Heart J 1995; 16 (Suppl N):19-30.
23. Tozzi R, Palladini G, Fallarini S, Nano R, Gatti C, Presotto C, et al. Matriz metalloprotease activity is enhanced in the compensated but not in the decompesated phase of pressure overload hypertrophy. Am J Hypertens 2007; 20:663-669.
24. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103:2303-2309.
25. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109:2143-2149.
26. Hori Y, Yoshioka K, Kanai K, Hoshi F, Itoh N, Higuchi S. Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats. Biol Pharm Bull 2011; 34:61-65.
27. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006; 47:770-779.
28. Sugden PH. Signaling pathways activated by vasoactive peptides in the cardiac myocyte and their role in myocardial pathologies. J Card Fail 2002; 8:S359-369.
29. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43:2028-2035.
30. Schellings MW, van Almen GC, Sage EH, Heymans S. Thrombospondins in the heart: potential functions in cardiac remodeling. J Cell Commun Signal 2009; 3:201-213.
31. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200:488-499.
32. Batlle M, Pérez-Villa F, Lázaro A, García-Pras E, Vallejos I, Sionis A, et al. Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling. Transplant Proc 2009; 41:2231-2233.
33. Chen YW, Pat B, Gladden JD, Zheng J, Powell P, Wei CC, et al. Dynamic molecular and histopathological changes in the extracellular matrix and inflammation in the transition to heart failure in isolated volume overload. Am J Physiol Heart Circ Physiol 2011; 300:H2251-H2260.
34. Schellings MW, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen RE, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009; 206:113-123.
35. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Boggs J, Lacy JM, et al. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in postsynthetic procollagen processing. Circulation 2009; 119:269-280.
36. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11:119-129.
37. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, et al. Eplerenone attenuates myocardial fibrosis in the angiotensin IIinduced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 2007; 49:261-268.